ARID1A and neoplasm: As ARID1A loss has been associated with improved response to immunotherapy across diverse tumor types [23] and ARID1A can directly interact with EZH2 to antagonize EZH2-mediated interferon response [24], identification of ARID1A mutations in aggressive soft tissue sarcomas may of great clinical significance for targeted therapy.